Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell & Gene Therapy and Cancer Immunotherapy Asia 2020

Cell & Gene Therapy and Cancer Immunotherapy Asia 2020 Agenda

Print Agenda

Thursday, 12 November 2020


Yasufumi KanedaConference Chair

Title to be Confirmed.
Yasufumi Kaneda, Professor and Vice-President/Provost, Osaka University, Japan


Osamu NurekiKeynote Presentation

Molecular Mechanism of CRISPR-Cas and Development of Novel Genome-Editing Tools Towards Gene Therapy
Osamu Nureki, Professor, The University of Tokyo, Japan

The CRISPR-associated endonuclease Cas9 can be targeted to specific genomic loci by single guide RNAs (sgRNAs). We have solved the crystal structures of Cas proteins, from 7 species, complexed with sgRNA and its target DNA at atomic resolutions. These high-resolution structures combined with functional analyses revealed the generality and diversity of molecular mechanism of RNA-guided DNA targeting by Cas nucleases, and uncovered the distinct mechanisms of PAM recognition. On the basis of the structures, we succeeded in changing the specificity of PAM recognition, which paves the way for rational design of new, versatile genome-editing technologies. We have generated single guanine recognizing Cas9 variants and mostly PMA-less Cas9 variants, which would be very useful for base editing and gene modulation using dCas9 as well as widening target space for genome editing.


Engineering of Cells For Cancer Immunotherapy
Noriko Shimasaki, Research Assistant Professor, Goh Foundation Director of Advanced Cellular Therapy Laboratory, National University of Singapore, Singapore

The dramatic clinical efficacy of T lymphocytes expressing chimeric antigen receptors has been demonstrated in B-cell malignancies. The great success suggests a potential of immune-cell based therapy for other hematological and solid malignancies. We have translated technologies developed in our research laboratory into large-scale procedures in compliance with current Good Manufacturing Practices guidelines. The developed methods are implemented to prepare cell products for infusion to patients. The translation into clinical application at an academic facility will be discussed.


Next-Generation Oncolytic Vaccinia Virus for Cancer Immuno-Virotherapy
Takafumi Nakamura, Associate Professor, Division of Molecular Medicine, Tottori University, Japan

Oncolytic virotherapy is a novel approach for cancer therapy. Vaccinia virus (VV), once widely used for smallpox vaccine, has been genetically engineered and used as an oncolytic virus for cancer virotherapy. The therapeutic index was successfully enhanced by stricter tumor-specific viral replication, stronger oncolytic potency, reduced viral antigenicity and optimized induction of anti-tumor immunity. Thus, our results support the clinical development of the next-generation oncolytic vaccinia virus.


Networked Imaging Flow Cytometry
Sadao Ota, Associate Professor, University of Tokyo, Japan


Hiroshi NagashimaKeynote Presentation

The Promise of Genome Edited Pigs for Organ Regeneration
Hiroshi Nagashima, Director and Professor, Meiji University International Institute for Bio-Resource Research, Japan

Generation of functional organs from pluripotent stem cells (PSCs) is one of the ultimate goals of regenerative medicine. We have advocated a concept of generating human organs from PSCs by organogenesis in xenogeneic animals. This concept consists of two fundamental technologies, i.e., induction of an empty developmental niche in the organogenesis of pig fetus and its compensation by exogenous iPSCs through blastocyst complementation. We have so far demonstrated the production of genetically modified pigs with an organogenesis-disabled phenotype in various organs, including pancreas, kidney, liver, and blood vessels. We also demonstrated the applicability of the blastocyst complementation technique in an allogenic setting for compensating the dysorganogenetic phenotypes of the pigs. Current challenges and future prospects of generating human organs by interspecific blastocyst complementation will be discussed.


Norio NakatsujiConference Chair

Title to be Confirmed.
Norio Nakatsuji, Chief Advisor, Stem Cell & Device Laboratory, Inc. (SCAD); Professor Emeritus, Kyoto University, Japan


Hiroshi KawamotoKeynote Presentation

Title to be Confirmed.
Hiroshi Kawamoto, Professor, Laboratory of Immunology, Institute for Frontier Life and Medical Sciences, Kyoto University, Japan


a-Synuclein Targeted Antisense Oligonucleotides For Treatment of Parkinson’s Disease
Hideki Mochizuki, Professor and Chairman, Osaka University Graduate School of Medicine, Japan

Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies and neurites predominantly composed of aggregated a-synuclein (SNCA). We designed and synthesized amido-bridged nucleic acids (AmNA)-modified antisense oligonucleotides (ASOs) that targeted SNCA for SNCA downregulation endogenously. AmNA-ASO-SNCA is a promising therapeutic strategy for SNCA-associated pathology in PD. I will present you a new technique to introduce this compound to the brain with focused ultrasound.


CELLINKThree-Dimensional Approach to Study Cancer Immunotherapy
Haruka Yoshie, Application Specialist, CELLINK

Cancer is known for its complexity and due to its complexity, treatment is difficult. A significant effort and progress have been made in cancer therapy, including cancer immunotherapy. To better understand the disease, it is important for the tumor microenvironment to be closely recapitulated in studying cancer models. There has been an increasing number of 3D cell culture studies recently as it represents the native environment of our body more accurately. There are several approaches to study 3D models including organoids and organ-on-a-chip. Here we present the 3D bioprinting technology and its recent applications in cancer immunotherapy. Furthermore, bioprinting applications in other cancer studies including drug screening and tumor-on-a-chip will be discussed.

Agenda is not currently available
Add to Calendar ▼2020-11-12 00:00:002020-11-13 00:00:00Europe/LondonCell and Gene Therapy and Cancer Immunotherapy Asia 2020Cell and Gene Therapy and Cancer Immunotherapy Asia 2020 in Kobe, JapanKobe,